HOUSTON, Sept. 9, 2004 (PRIMEZONE) -- Celgene (Nasdaq:CELG) Chairman and CEO John W. Jackson will appear on "Corporate Strategies with Tim Connolly" this Sunday night September 12 at 9:10 pm EDT. Listeners may call in questions live and toll free to Tim Connolly or technical analyst Mike King at 1-866-606-TALK (8255). The Business TalkRadio Network Show may be heard on KSEV AM 700 in Houston, on over 375 affiliate stations nationwide listed at CRN1 www.cableradionetwork.com, or on the Internet at www.businesstalkradio.net. This hour of "Corporate Strategies with Tim Connolly" is hosted by Tim Connolly of Corporate Strategies Merchant Bankers (www.corporate-strategies.net). Noted Economist Mike King of Princeton Research provides live technical analysis for the show.
About Celgene Corporation:
Celgene Corporation, headquartered in Warren, New Jersey, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene's THALOMID net sales in the second quarter of 2004 increased 35.9% to $74.6 million from $54.9 million in the second quarter of 2003. THALOMID is used in patients with multiple myeloma. Celgene has increased spending in R&D in developing REVLIMID, ACTIMID(tm) and the newest IMID(r), as well as other high potential investigational compounds including kinases, benzopyrans, ligases, tubulin inhibitors and placentally-derived stem cell programs.
"Celgene continued to deliver increasing revenue and accelerating profitability while continuing to invest in the R&D that is essential to our future success and maintaining full rights to our core proprietary products," as said by John W. Jackson. "Furthermore, during the second quarter, THALOMID's potential in hematological and solid tumor cancers was underscored again by more peer-reviewed publications in the Journal of Clinical Oncology and presentations of seminal clinical studies such as the Phase III ECOG (E1A00) at this year's ASCO meeting. Celgene looks forward to an eventful second-half of 2004 with meaningful milestones including regulatory announcements, key presentations and publications reporting new clinical data on our leading products at major medical meetings, as well as further advancement of our rich product pipeline."
"Corporate Strategies with Tim Connolly" is live talk radio ... with the Titans of Business who move financial markets! The show is hosted by Tim Connolly, CEO of Merchant Banker Corporate Strategies, Inc. The Executive Producer of the show is broadcast news veteran Jan Carson, an award-winning journalist with more than 20 years' experience as a top-rated television news anchor and reporter for NBC, ABC and CBS network affiliates. "Corporate Strategies with Tim Connolly" features financial experts from across the nation providing the latest intelligence on equities, income investments, and a variety of risk, equity and option strategies. Recent guests have included Landry's CEO Tilman Fertitta, Tobin Smith, John Murphy, Mario Gabelli, former SEC Chairman Arthur Levitt, former Compaq CEO Eckard Pfeiffer, Money Manager Louis Navellier, and many others.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.